摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-乙酰氧基-3-O-(2-乙酰氧基-2-脱氧-B-D-吡喃糖苷)-2-脱氧-A-D-半乳糖苷-4-硝基苯酯 | 125455-64-3

中文名称
2-乙酰氧基-3-O-(2-乙酰氧基-2-脱氧-B-D-吡喃糖苷)-2-脱氧-A-D-半乳糖苷-4-硝基苯酯
中文别名
2-乙酰氧基-3-O-(2-乙酰氧基-2-脱氧-β-D-吡喃糖苷)-2-脱氧-α-D-半乳糖苷-4-硝基苯酯
英文名称
p-nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranosyl-(1->3)-2-acetamido-2-deoxy-α-D-galactopyranoside
英文别名
GlcNAcβ1->3GalNAcα-pnp;4-Nitrophenyl 2-acetamido-3-O-(2-acetamido-2-deoxy-b-D-glucopyranosyl)-2-deoxy-a-D-galactopyranoside;N-[(2R,3R,4R,5S,6R)-2-[(2R,3R,4R,5R,6R)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxan-4-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
2-乙酰氧基-3-O-(2-乙酰氧基-2-脱氧-B-D-吡喃糖苷)-2-脱氧-A-D-半乳糖苷-4-硝基苯酯化学式
CAS
125455-64-3
化学式
C22H31N3O13
mdl
MFCD00079483
分子量
545.5
InChiKey
HXQAUFSCNOLKJP-VHMNXSECSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    225-230°C
  • 沸点:
    965.4±65.0 °C(Predicted)
  • 密度:
    1.55±0.1 g/cm3(Predicted)
  • 溶解度:
    水(稍微加热)

计算性质

  • 辛醇/水分配系数(LogP):
    -2
  • 重原子数:
    38
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.636
  • 拓扑面积:
    242
  • 氢给体数:
    7
  • 氢受体数:
    13

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S22,S26,S36
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    29389090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Specificity of β1,4-galactosyltransferase inhibition by 2-naphthyl 2-butanamido-2-deoxy-1-thio-β-D-glucopyranoside
    作者:Yin Gao、Carmen Lazar、Walter A. Szarek、Inka Brockhausen
    DOI:10.1007/s10719-010-9312-3
    日期:2010.10
    Inhibitors of Galactosyltransferase (GalT) have the potential of reducing the amounts of adhesive carbohydrates on secreted and cell surface-bound glycoproteins. We recently found a potent inhibitor of β4GalT, 2-naphthyl 2-butanamido-2-deoxy-1-thio-β-D-glucopyranoside (compound 612). In this work, we have tested compound 612 for the specificity of its inhibition and examined its effect on GalT, and on GlcNAc- and GalNAc-transferases in homogenates of different cell lines, as well as on recombinant glycosyltransferases. Compound 612 was found to be a specific inhibitor of β4GalT. The specificity of recombinant human β3GalT5 that also acts on GlcNAc-R substrates, revealed similarities to bovine milk β4GalT. However, 612 was a poor substrate and not an inhibitor for β3GalT5. To further determine the specific structures responsible for the inhibitory property of 612, we synthesized (2-naphthyl)-2-butanamido-2-deoxy-β-D-glucopyranosylamine (compound 629) containing nitrogen in the glycosidic linkage, and compared it to other naphthyl and quinolinyl derivatives of GlcNAc as substrates and inhibitors. Compound 629 was a substrate for both β4GalT and β3GalT5. This suggests that properties of 612 other than the presence of the naphthyl ring alone were responsible for its inhibitory action. The results suggest a usefulness of 612 in specifically blocking the synthesis of type 2 chains and thus epitopes attached to type 2 chains. In addition, 612 potently inhibits β4GalT in cell homogenates and thus allows assaying β3GalT activity in the presence of β4GalT.
    半乳糖基转移酶(GalT)抑制剂有可能减少分泌的和细胞表面结合的糖蛋白上粘附的碳水化合物的数量。我们最近发现了一种有效的 β4GalT 抑制剂--2-萘基 2-丁酰胺基-2-脱氧-1-硫代-β-D-吡喃葡萄糖苷(化合物 612)。在这项工作中,我们测试了化合物 612 抑制作用的特异性,并研究了它对 GalT、不同细胞系匀浆中的 GlcNAc 和 GalNAc 转化酶以及重组糖基转移酶的影响。研究发现,化合物 612 是 β4GalT 的特异性抑制剂。重组人 β3GalT5 也作用于 GlcNAc-R 底物,其特异性与牛乳 β4GalT 相似。然而,612 是一种较差的底物,而不是 β3GalT5 的抑制剂。为了进一步确定 612 抑制性的具体结构,我们合成了糖苷键中含有氮的 (2-naphthyl)-2-butanamido-2-deoxy-β-D-glucopyranosylamine (化合物 629),并将其与 GlcNAc 的其他萘基和喹啉基衍生物作为底物和抑制剂进行了比较。化合物 629 既是β4GalT 的底物,也是β3GalT5 的底物。这表明,612 的抑制作用不仅仅是由于萘环的存在。结果表明,612 可特异性地阻断 2 型链的合成,从而阻断附着在 2 型链上的表位。此外,612 还能有效抑制细胞匀浆中的β4GalT,因此可以在存在 β4GalT 的情况下检测 β3GalT 的活性。
  • Protein particles for therapeutic and diagnostic use
    申请人:——
    公开号:US20020142046A1
    公开(公告)日:2002-10-03
    Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.
    通过在颗粒组合物中加入稳定剂,可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外,还公开了交联或非交联的纤维蛋白原涂层微粒,以及它们作为与血小板和自身的共聚物的用途,以达到缩短出血时间和增强凝血酶效果的目的。
  • US5616311A
    申请人:——
    公开号:US5616311A
    公开(公告)日:1997-04-01
  • US5725804A
    申请人:——
    公开号:US5725804A
    公开(公告)日:1998-03-10
  • US6391343B1
    申请人:——
    公开号:US6391343B1
    公开(公告)日:2002-05-21
查看更多